𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: A placebo-controlled trial

✍ Scribed by Ulrich Beuers; Ulrich Spengler; Wolfgang Kruis; ülker Aydemir; Baldur Wiebecke; Walter Heldwein; Marlene Weinzierl; Gerd R. Pape; Tilman Sauerbruch; Gustav Paumgartner

Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
855 KB
Volume
16
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Metronidazole and ursodeoxycholic acid f
Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: A randomized placebo-controlled trial
✍ Martti Färkkilä; Anna-Liisa Karvonen; Heimo Nurmi; Hannu Nuutinen; Matti Taavits 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 1 views

No effective medical therapy is currently available for primary sclerosing cholangitis (PSC). Ursodeoxycholic acid (UDCA) improves liver enzymes, but its effect on liver histology is controversial. Metronidazole (MTZ) prevents PSC-like liver damage in animal models and reduces intestinal permeabilit

High-dose ursodeoxycholic acid for the t
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis
✍ Keith D. Lindor; Kris V. Kowdley; Velimir A. C. Luketic; M. Edwyn Harrison; Timo 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 319 KB 👁 1 views

Previous controlled trials are inconclusive regarding the efficacy of ursodeoxycholic acid (UDCA) for treating primary sclerosing cholangitis (PSC). One hundred fifty adult patients with PSC were enrolled in a long-term, randomized, double-blind controlled trial of highdose UDCA (28-30 mg/kg/day) ve

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
✍ Burton Combes; Robert L. Carithers Jr.; Willis C. Maddrey; Danyu Lin; Dr Mary F. 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 792 KB

One hundred fifty-one patients with primary biliary cirrhosis (PBC) grouped into four strata based on entry serum bilirubin (<2 mg/dL vs. 2 mg/dL or greater) and liver histology (stages I, 1 1 vs. stages 111, IV-Ludwig criteria) were randomized within each stratum to ursodiol or placebo given in a s

Ursodeoxycholic acid as adjunctive thera
Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: A randomized placebo-controlled treatment trial
✍ Albert J. Czaja; Herschel A. Carpenter; Keith D. Lindor 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 1 views

To evaluate the efficacy of ursodeoxycholic acid as adjunctive therapy in type 1 autoimmune hepatitis, 37 patients who had experienced treatment failure, repeated relapse, or incomplete response were randomized to ursodeoxycholic acid (13-15 mg/kg daily) or placebo for 6 months in addition to their